SynthesisBMC musculoskeletal disorders2025
The effect of Jintiange capsules on pain in patients with primary osteoporosis: a systematic review and meta-analysis.
Synthesis in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and Safety of Celecoxib Combined With Jintiange Capsules for the Treatment of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Medical science monitor : international medical journal of experimental and clinical research · 2026Trial
- Traditional Chinese Medicine for osteoporosis management: from molecular mechanisms to drug discovery.Chinese medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTo evaluate the effectiveness of Jintiange capsules (JTG) in relieving pain in patients with primary osteoporosis (POP).
methodsA systematic review of the literature was conducted through seven databases, including PubMed, Web of Science, Cochrane Library, Embase, Chinese National Knowledge Infrastructure, Wanfang Database and SinoMed, from inception to October 2023. The control group was given conventional anti-osteoporosis drug therapy such as Alfacalcidol soft capsules, Alendronate sodium tablets, Caltrate D3, etc. The experimental group was treated with JTG alone or in combination with JTG on the basis of the drugs used in the control group. The primary outcome measure was the visual analog scale (VAS). Stata SE-64 software was used to conduct meta-analyses of the final included studies.
resultsA total of 2916 participants were included in 21 articles. The results of meta-analysis showed that JTG relieved pain (WMD: -2.51; 95% CI: -3.30, -1.71; p < 0.05), improved the bone mineral density (BMD) of femoral neck (WMD: 0.83; 95% CI: 0.33, 1.33; p < 0.05) and lumbar (WMD: 1.14; 95% CI: 0.67, 1.62; p < 0.05), improved oswestry disability index (ODI) (WMD: -1.79; 95% CI: -3.05, -0.54; p < 0.05), enhanced timed up and go test (TUG) (WMD: -2.61; 95% CI: -4.60, -0.62; p < 0.05) and decreased fracture incidence (WMD: 0.37; 95% CI: 0.15, 0.93; p < 0.05).
conclusionIn terms of relieving pain, improving BMD, improving activity function, and improving gait and preventing fracture, JTG is a good choice for patients with osteoporosis (OP).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.